Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical oxybutynin in children with neurogenic bladder due to spina bifida
2022-501902-36-00Phase 3Authorised
- Sponsor
- CHRU Nancy
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in neurogenic bladder, overactive bladder (OAB) and spina bifida (SB) comparing Intravesical oxybutynin (VESOXX) with Intravesical 0.9% sodium chloride (placebo/control) (2 arms). Primary endpoint: Evolution of maximal bladder capacity at 4 weeks of treatment. Planned start Jan 2025; status: authorised.
02
Drugs
intravesical oxybutynin
03
Conditions
neurogenic bladderoveractive bladder (OAB)spina bifida (SB)
Beyond the preview
Go deeper on 2022-501902-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501902-36-00.